Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein (Q36020263)

11 August 2017

1 reference

title

Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein (English)

1 reference

11 August 2017

1 reference

James M Backes

1

1 reference

11 August 2017

Cheryl A Gibson

series ordinal

2

1 reference

11 August 2017

language of work or name

English

0 references

publication date

25 January 2005

1 reference

Annals of Pharmacotherapy

11 August 2017

published in

1 reference

11 August 2017

volume

39

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

523-526

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

11 August 2017

cites work

1 reference

Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients

21 January 2018

1 reference

Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects.

21 January 2018

1 reference

Pravastatin treatment in combined hyperlipidaemia. Effect on plasma lipoprotein levels and size

21 January 2018

1 reference

Effect of fluvastatin on low-density lipoprotein peak particle diameter.

21 January 2018

1 reference

Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates

21 January 2018

1 reference

Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux

21 January 2018

1 reference

Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype

21 January 2018

1 reference

Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action

21 January 2018

1 reference

Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia

21 January 2018

1 reference

Effects of extended-release niacin on lipoprotein subclass distribution

21 January 2018

1 reference

Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management

21 January 2018

1 reference

Differential effects of nicotinic acid in subjects with different LDL subclass patterns

21 January 2018

1 reference

Use of niacin, statins, and resins in patients with combined hyperlipidemia.

21 January 2018

1 reference

Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies

21 January 2018

1 reference

A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients

21 January 2018

1 reference

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1E322

1 reference

release_m2ykrzmm5remnido4c7qtjqhim

11 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/m2ykrzmm5remnido4c7qtjqhim

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference